info@buecher-doppler.ch
056 222 53 47
Warenkorb
Ihr Warenkorb ist leer.
Gesamt
0,00 CHF
  • Start
  • Therapeutic Targeting of RAS Mutant Cancers

Therapeutic Targeting of RAS Mutant Cancers

Angebote / Angebote:

The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.
Folgt in ca. 15 Arbeitstagen

Preis

30,50 CHF